201 related articles for article (PubMed ID: 26616003)
1. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics.
Geale K; Henriksson M; Schmitt-Egenolf M
Br J Dermatol; 2016 Mar; 174(3):579-87. PubMed ID: 26616003
[TBL] [Abstract][Full Text] [Related]
2. Inequalities in access to biological treatments for psoriasis: results from the Italian Psocare registry.
Naldi L; Cazzaniga S; Di Mercurio M; Grossi E; Addis A;
Br J Dermatol; 2017 May; 176(5):1331-1338. PubMed ID: 27973689
[TBL] [Abstract][Full Text] [Related]
3. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice.
Calara PS; Norlin JM; Althin R; Carlsson KS; Schmitt-Egenolf M
BioDrugs; 2016 Apr; 30(2):145-51. PubMed ID: 26883786
[TBL] [Abstract][Full Text] [Related]
5. Reducing patient copayment levels for topical and systemic treatments in plaque psoriasis as a case for evidence-based, sustainable pharmaceutical policy change in Greece.
Souliotis K; Golna C; Kani C; Litsa P
J Med Econ; 2016 Nov; 19(11):1021-1026. PubMed ID: 27207488
[TBL] [Abstract][Full Text] [Related]
6. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry.
van den Reek JMPA; Seyger MMB; van Lümig PPM; Driessen RJB; Schalkwijk CJM; Berends MAM; van de Kerkhof PCM; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):615-623. PubMed ID: 29121430
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Phototherapy in the Age of Biologics.
Calzavara-Pinton P; Zanca A; Arisi M; Rossi MT; Zane C; Venturini M; Ortel B
Dermatology; 2018; 234(5-6):166-172. PubMed ID: 30205372
[TBL] [Abstract][Full Text] [Related]
8. Costs of Common Psoriasis Medications, 2010-2014.
James SM; Hill DE; Feldman SR
J Drugs Dermatol; 2016 Mar; 15(3):305-8. PubMed ID: 26954315
[TBL] [Abstract][Full Text] [Related]
9. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
Medina-Gil C; Dehesa L; Vega A; Kerdel F
Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
[TBL] [Abstract][Full Text] [Related]
11. Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 20.
Ponnambath N; Kalavala M; Anstey AV; Piguet V; Ingram JR
Clin Exp Dermatol; 2016 Jan; 41(1):95-6. PubMed ID: 25817265
[No Abstract] [Full Text] [Related]
12. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
[TBL] [Abstract][Full Text] [Related]
13. The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men.
Hägg D; Eriksson M; Sundström A; Schmitt-Egenolf M
PLoS One; 2013; 8(5):e63619. PubMed ID: 23691076
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
15. Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.
van den Reek JM; van Lüumig PP; Otero ME; Zweegers J; van de Kerkhof PC; Ossenkoppele PM; Njoo MD; Mommers JM; Koetsier MI; Arnold WP; Sybrandy-Fleuren BA; Kuijpers AL; Andriessen MP; Seyger MM; Kievit W; de Jong EM
Br J Dermatol; 2014 May; 170(5):1158-65. PubMed ID: 24484403
[TBL] [Abstract][Full Text] [Related]
16. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
[TBL] [Abstract][Full Text] [Related]
17. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
18. Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs.
Feldman SR; Levi E; Pathak P; Kakatkar S; Balkrishnan R
J Med Econ; 2013 Dec; 16(12):1405-13. PubMed ID: 24063352
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study.
Tang MM; Chang CC; Chan LC; Heng A
Int J Dermatol; 2013 Mar; 52(3):314-22. PubMed ID: 23414155
[TBL] [Abstract][Full Text] [Related]
20. Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database.
Noe MH; Shin DB; Doshi JA; Margolis DJ; Gelfand JM
J Drugs Dermatol; 2019 Aug; 18(8):745-750. PubMed ID: 31424706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
